Human Siglec-1/CD169 Antibody Summary
Ser20-Gln1641
Accession # Q9BZZ2
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Scientific Data
View Larger
Detection of Human Siglec‑1/CD169 by Western Blot. Western blot shows lysates of SH‑SY5Y human neuroblastoma cell line and human lymph node. PVDF membrane was probed with 0.5 µg/mL of Sheep Anti-Human Siglec‑1/CD169 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF5197) followed by HRP-conjugated Anti-Sheep IgG Secondary Antibody (HAF016). A specific band was detected for Siglec‑1/CD169 at approximately 180-200 kDa (as indicated). This experiment was conducted under reducing conditions and using Western Blot Buffer Group 1.
View Larger
Cell Adhesion Mediated by Siglec‑1/CD169 and Neutralization by Human Siglec‑1/CD169 Antibody. Recombinant Human Siglec-1/CD169 Fc Chimera (Catalog # 5197-SL), immobilized onto a microplate, supports the adhesion of human red blood cells in a dose-dependent manner (orange line). Adhesion elicited by Recombinant Human Siglec-1/CD169 Fc Chimera (5 µg/mL) is neutralized (green line) by increasing concentrations of Sheep Anti-Human Siglec-1/CD169 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF5197). The ND50 is typically 1.5-7.5 µg/mL.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: Siglec-1/CD169
Siglecs are sialic acid specific I-type lectins that belong to the immunoglobulin superfamily. Structurally, they are transmembrane proteins with an N-terminal Ig-like V‑set domain followed by varying numbers of Ig-like C2-set domains (1, 2). Human Siglec-1, also known as sialoadhesin and CD169, is a 175‑185 kDa glycoprotein. It contains a 1622 amino acid (aa) extracellular domain (ECD) with one Ig-like V‑set domain and 16 Ig-like C2-set domains, a 21 aa transmembrane segment, and a 44 aa cytoplasmic domain (3). Within the ECD, human Siglec-1 shares approximately 70% aa sequence identity with mouse and rat Siglec-1. Alternate splicing generates a potentially soluble form of the ECD, and a second isoform with a substituted cytoplasmic domain. Siglec-1 expression is restricted to lymph node and splenic macrophages, plus some tissue macrophages (3). The adhesive function of Siglec-1 is supported by the N-terminal Ig-like domain which shows a selectivity for alpha 2,3‑linked sialic acid residues (3‑5). Siglec-1 binds a number of sialylated molecules including the mannose receptor, MGL1, MUC1, PSGL-1, and different glycoforms of CD43 (6‑9). Its binding capacity can be masked by endogenous sialylated molecules (10, 11). The sialylated and sulfated N-linked carbohydrates that modify Siglec-1 itself are required for ligand binding (6, 7). Siglec-1 is expressed on dendritic cells following rhinovirus exposure, and these DC promote T cell anergy (12). It is also induced on circulating monocytes during systemic sclerosis and HIV-1 infection (13‑15). Siglec-1 can trap HIV-1 particles for trans infection of permissive cells (14).
- Varki, A. and T. Angata (2006) Glycobiology 16:1R.
- Crocker, P.R. et al. (2007) Nat. Rev. Immunol. 7:255.
- Hartnell, A. et al. (2001) Blood 97:288.
- Nath, D. et al. (1995) J. Biol. Chem. 270:26184.
- Crocker, P.R. et al. (1991) EMBO J. 10:1661.
- Martinez-Pomares, L. et al. (1999) J. Biol. Chem. 274:35211.
- Kumamoto, Y. et al. (2004) J. Biol. Chem. 279:49274.
- Nath, D. et al. (1999) Immunology 98:213.
- van den Berg, T.K. et al. (2001) J. Immunol. 166:3637.
- Nakamura, K. et al. (2002) Glycobiology 12:209.
- Barnes, Y.C. et al. (1999) Blood 93:1245.
- Kirchberger, S. et al. (2005) J. Immunol. 175:1145.
- York, M.R. et al. (2007) Arthritis Rheum. 56:1010.
- Rempel, H. et al. (2008) PloS ONE 3:e1967.
- van der Kuyl, A.C. et al. (2007) Plos ONE 2:e257.
Product Datasheets
Citations for Human Siglec-1/CD169 Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
3
Citations: Showing 1 - 3
Filter your results:
Filter by:
-
Gene Expression Profiling of Lymph Node Sub-Capsular Sinus Macrophages in Cancer
Authors: Danilo Pellin, Natalie Claudio, Zihan Guo, Tahereh Ziglari, Ferdinando Pucci
Frontiers in Immunology
-
Distinct patterns and prognostic values of tumor-infiltrating macrophages in hepatocellular carcinoma and gastric cancer
Authors: JQ Li, XJ Yu, YC Wang, LY Huang, CQ Liu, L Zheng, YJ Fang, J Xu
J Transl Med, 2017-02-15;15(1):37.
Species: Human
Sample Types: Whole Tissue
Applications: IHC-P -
Siglec-1 initiates formation of the virus-containing compartment and enhances macrophage-to-T cell transmission of HIV-1
Authors: JE Hammonds, N Beeman, L Ding, S Takushi, AC Francis, JJ Wang, GB Melikyan, P Spearman
PLoS Pathog, 2017-01-27;13(1):e1006181.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Human Siglec-1/CD169 Antibody
There are currently no reviews for this product. Be the first to review Human Siglec-1/CD169 Antibody and earn rewards!
Have you used Human Siglec-1/CD169 Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
